TEVA 4.100% 01Oct2046 Corp (USD)

Bond Factsheet

Teva Pharmaceutical Finance Netherlands III B.V.

Indicative

Full Lot

Bid Price

71.480

Change in Bid Price

remove 0.140

Bid Yield (%)

6.713 %

Change in Bid Yield

0.016

Ask Price

71.854

Change in Ask Price

remove 0.161

Ask Yield (%)

6.670 %

Change in Ask Yield

0.019

Indicative price as of 06 Oct 2026, 4:04pm

chevron_leftchevron_right

Bond Information

Teva Pharmaceutical Finance Netherlands III B.V. operates as a special purpose entity. The Company was formed for the purpose of issuing debt securities to repay existing credit facilities, refinance indebtedness, and for acquisition purposes.

Bond Issuer

Teva Pharmaceutical Finance Netherlands III B.V.

Guarantor

Teva Pharmaceutical Industries Ltd

Announcement Date

18 Jul 2016

Issue Date

21 Jul 2016

Maturity Date

01 Oct 2046

Years to Maturity / Next Call

19.998 / -

Modified Duration

12.163 @ 05 Oct 2026

Issue / Reoffer Price

99.167

Issue / Reoffer Yield

4.148

Coupon Type

Fixed

Annual Coupon Rate

4.100

Coupon Frequency

Semi Annually

Seniority

Senior Unsecured

Reference Rate

ISIN

US88167AAF84

CUSIP

88167AAF8

Bond Currency

USD

Total Issue Size

2,000,000,000

Min. Investment Quantity (Nominal)

USD 2,000

Incremental Quantity (Nominal)

USD 1,000

Bond Type

Corporate

Bond Sector

Health Care

Bond Sub Sector

Pharmaceuticals

Issuer Credit Rating (S&P/ Fitch)

***/ N.R

Bond Credit Rating (S&P/ Fitch)

***/ BBB-

Shariah Compliant

Exchange Listed

Others

Bond Feature(s)

Make Whole Call

Teva Finance may redeem the notes of any series, in whole or in part, at any time or from time to time, on at least 20 days’, but not more than 60 days’, prior notice. The notes of each series will be redeemable at a redemption price equal to the greater of

(1) 100% of the principal amount of the notes to be redeemed

(2) the sum of the present values of the Remaining Scheduled Payments (as defined under “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) discounted, on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months), at a rate equal to the sum of the Treasury Rate (as defined in “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) plus 12.5 basis points, in the case of the 2018 notes, 15 basis points, in the case of the 2019 notes, 20 basis points, in the case of the 2021 notes, 25 basis points, in the case of the 2023 notes, 25 basis points, in the case of the 2026 notes, or 30 basis points, in the case of the 2046 notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

Additional Note

Special Mandatory Redemption

If the closing of the Actavis Generics acquisition does not occur on or prior to October 26, 2016, or if the Master Purchase Agreement is terminated at any time prior thereto, we will be required to redeem the notes on the special redemption date (as defined below) at a redemption price equal to 101% of their aggregate principal amount (the “special redemption price”), plus accrued and unpaid interest, if any, from the date of initial issuance of the notes up to, but not including, the special redemption date.

The “special redemption date” means the date fixed for any special mandatory redemption in a special mandatory redemption notice (as defined below).

Bondsupermart strives to ensure the accuracy and relevance of the information provided here. If the information is not up-to-date or erroneous, we appreciate feedback to keep it accurate.

Coupon Dates	Coupon Receive	Principal Amount	Cash Flow

No Data